[go: up one dir, main page]

MX2014006594A - Compuestos de enzimas lisosomales apuntados. - Google Patents

Compuestos de enzimas lisosomales apuntados.

Info

Publication number
MX2014006594A
MX2014006594A MX2014006594A MX2014006594A MX2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A
Authority
MX
Mexico
Prior art keywords
compounds
lysosomal enzyme
compound
targeting moiety
enzyme compounds
Prior art date
Application number
MX2014006594A
Other languages
English (en)
Inventor
Dominique Boivin
Jean-Paul Castaigne
Michel Demeule
Sasmita Tripathy
Jean-Christophe Currie
Simon Lord-Dufour
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of MX2014006594A publication Critical patent/MX2014006594A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está relacionada con un compuesto que incluye un enzima lisosomal y una fracción que apunta, por ejemplo, donde el compuesto es una proteína de fusión que incluye una 2-sulfatasa iduronato y Angiopep-2. En ciertas formas de realización, estos compuestos, debido a la presencia de la fracción que apunta, pueden cruzar la barrera hematoencefálica o acumularse en el lisosoma de manera más efectiva que la enzima sola. La invención también se refiere a métodos para tratar desórdenes del almacenamiento lisosomal (v. gr., mucopolisacarido-sis tipo II) usando tales compuestos.
MX2014006594A 2011-12-01 2012-11-30 Compuestos de enzimas lisosomales apuntados. MX2014006594A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161565764P 2011-12-01 2011-12-01
US201261596515P 2012-02-08 2012-02-08
US201261660564P 2012-06-15 2012-06-15
PCT/CA2012/050867 WO2013078564A2 (en) 2011-12-01 2012-11-30 Targeted lysosomal enzyme compounds

Publications (1)

Publication Number Publication Date
MX2014006594A true MX2014006594A (es) 2015-09-16

Family

ID=48536183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006594A MX2014006594A (es) 2011-12-01 2012-11-30 Compuestos de enzimas lisosomales apuntados.

Country Status (11)

Country Link
US (1) US20150037311A1 (es)
EP (1) EP2785838A4 (es)
JP (1) JP2015505824A (es)
CN (1) CN104145015A (es)
AU (1) AU2012344702A1 (es)
BR (1) BR112014013161A2 (es)
CA (1) CA2857567A1 (es)
HK (2) HK1200189A1 (es)
MX (1) MX2014006594A (es)
RU (1) RU2014126484A (es)
WO (1) WO2013078564A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368941T3 (es) 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
EP1907009A4 (en) 2005-07-15 2009-09-02 Angiochem Inc USE OF APROTININ POLYPEPTIDES AS CARRIER IN PHARMACEUTICAL CONJUGATES
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
PL2279008T3 (pl) 2008-04-18 2020-03-31 Angiochem Inc. Kompozycje farmaceutyczne paklitakselu, analogów paklitakselu lub koniugatów paklitakselu oraz powiązane sposoby wytwarzania i zastosowanie
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
CA2740317A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
US8853353B2 (en) 2008-12-17 2014-10-07 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
CA2766537A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
WO2013185235A1 (en) * 2012-06-15 2013-12-19 Angiochem Inc. Targeted iduronidase compounds
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
BR112015022780A2 (pt) 2013-03-15 2018-02-06 Amicus Therapeutics Inc reticuladores de produto químico
WO2014194428A1 (en) * 2013-06-06 2014-12-11 Angiochem Inc. Targeted heparan sulfatase compounds
EP3019515B1 (en) * 2013-07-11 2019-08-21 Novartis AG Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
JP6675333B2 (ja) * 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP3904389A1 (en) 2017-10-02 2021-11-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
EP4132584A4 (en) * 2020-04-07 2024-05-01 The Regents Of The University Of California MANUFACTURE OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTIC AGENTS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463473A1 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Targeted therapeutic proteins
CA2487815A1 (en) * 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
AU2003286870A1 (en) * 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
EP1877099B1 (en) * 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
WO2009079790A1 (en) * 2007-12-20 2009-07-02 Angiochem Inc. Polypeptide-nucleic acid conjugates and uses thereof
WO2010063124A1 (en) * 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
MX2011005963A (es) * 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
JP2013506697A (ja) * 2009-10-06 2013-02-28 アンジオケム インコーポレーテッド 治療薬を輸送するための組成物と方法
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
WO2013078562A2 (en) * 2011-12-01 2013-06-06 Angiochem Inc. Targeted enzyme compounds and uses thereof

Also Published As

Publication number Publication date
BR112014013161A2 (pt) 2019-09-24
HK1204002A1 (en) 2015-11-06
JP2015505824A (ja) 2015-02-26
CA2857567A1 (en) 2013-06-06
WO2013078564A3 (en) 2013-09-06
US20150037311A1 (en) 2015-02-05
CN104145015A (zh) 2014-11-12
WO2013078564A2 (en) 2013-06-06
AU2012344702A1 (en) 2014-06-19
EP2785838A4 (en) 2015-07-01
EP2785838A2 (en) 2014-10-08
HK1200189A1 (en) 2015-07-31
RU2014126484A (ru) 2016-02-10

Similar Documents

Publication Publication Date Title
MX2014006594A (es) Compuestos de enzimas lisosomales apuntados.
WO2013078562A3 (en) Targeted iduronate-2-sulfatase compounds
MX2014015551A (es) Compuestos iduronidasa apuntados.
PH12020550510A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes
PH12019550261A1 (en) Compositions and methods for internalizing enzymes
WO2010148253A3 (en) Formulations for lysosomal enzymes
PH12018501074A1 (en) Compositions and methods for internalizing enzymes
MX367024B (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y usos de las mismas.
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
UA114090C2 (uk) Сполуки, що інгібують металоферменти
EA201490036A1 (ru) Соединения, ингибирующие металлоферменты
MX347808B (es) Variantes de plasminogeno y plasmina.
TN2012000280A1 (en) Methods of administering pirfenidone therapy
AU2011270668A8 (en) CNS delivery of therapeutic agents
IN2014CN02584A (es)
MX337248B (es) Variantes de plasminogeno y plasmina.
WO2013026740A3 (en) Methods and means to modify a plant genome
WO2011163652A3 (en) Treatment of sanfilippo syndrome type b
MX354776B (es) Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal.
WO2013091897A8 (en) Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
EP2712291A4 (en) N1 AND N2 CARBAMOYL-1,2,3-TRIAZOL SERINE HYDROLASE INHIBITORS AND METHOD THEREFOR
WO2013119946A8 (en) Long chain base sphingosine kinase inhibitors
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
MX349801B (es) Sustratos de enzimas de ácido nucleico.